Stem definition | Drug id | CAS RN |
---|---|---|
4677 | 26833-87-4 |
None
Property | Value | Reference |
---|---|---|
Vd (Volume of distribution) | 1.80 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 2.96 mL/min/kg | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 9.80 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Oct. 26, 2012 | FDA | IVAX INTL |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Bone marrow failure | 63.96 | 44.74 | 20 | 470 | 29649 | 46655923 |
Platelet count decreased | 52.70 | 44.74 | 24 | 466 | 100000 | 46585572 |
Injection site erythema | 49.33 | 44.74 | 21 | 469 | 74406 | 46611166 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Injection site erythema | 58.28 | 40.90 | 17 | 436 | 13817 | 29938208 |
Platelet count decreased | 45.86 | 40.90 | 25 | 428 | 106104 | 29845921 |
Blood count abnormal | 43.27 | 40.90 | 13 | 440 | 11639 | 29940386 |
Source | Code | Description |
---|---|---|
ATC | L01XX40 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Other antineoplastic agents |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D000972 | Antineoplastic Agents, Phytogenic |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D011500 | Protein Synthesis Inhibitors |
CHEBI has role | CHEBI:35610 | cytostatic |
CHEBI has role | CHEBI:48001 | protein synthesis inhibitors |
CHEBI has role | CHEBI:68495 | type i programmed cell-death inducer |
CHEBI has role | CHEBI:149553 | anti-coronaviral agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Chronic myeloid leukemia | indication | 92818009 | DOID:8552 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 12.86 | acidic |
pKa2 | 8.15 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
SARS-CoV-2 | Virus | INHIBITOR | EC50 | 5.59 | SCIENTIFIC LITERATURE |
ID | Source |
---|---|
D08956 | KEGG_DRUG |
4031782 | VUID |
N0000186058 | NUI |
24316-19-6 | SECONDARY_CAS_RN |
4031782 | VANDF |
4031814 | VANDF |
C2709279 | UMLSCUI |
C3528000 | UMLSCUI |
CHEBI:71019 | CHEBI |
HMT | PDB_CHEM_ID |
CHEMBL46286 | ChEMBL_ID |
DB04865 | DRUGBANK_ID |
D000077863 | MESH_DESCRIPTOR_UI |
285033 | PUBCHEM_CID |
7454 | IUPHAR_LIGAND_ID |
8885 | INN_ID |
6FG8041S5B | UNII |
84MI6OYN4Z | UNII |
65305 | PUBCHEM_CID |
1356689 | RXNORM |
194347 | MMSL |
27023 | MMSL |
d07573 | MMSL |
009753 | NDDF |
421021001 | SNOMEDCT_US |
421815001 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
SYNRIBO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63459-177 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 3.50 mg | SUBCUTANEOUS | NDA | 27 sections |